לוסרטה 50 Իսրայել - եբրայերեն - Ministry of Health

לוסרטה 50

cts chemical industries ltd, israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losartan indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losartan on the primary composite end point

לוסרטה 12.5 Իսրայել - եբրայերեն - Ministry of Health

לוסרטה 12.5

cts chemical industries ltd, israel - losartan potassium - טבליה - losartan potassium 12.5 mg - losartan - losartan - hypertension : losartan is indicated for the treatment of hypertension. heart failure: losartan is indicated for the treatment of heart failure (nyha ii) when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended.

לוסרטה פלוס Իսրայել - եբրայերեն - Ministry of Health

לוסרטה פלוס

cts chemical industries ltd, israel - hydrochlorothiazide; losartan potassium - טבליה - hydrochlorothiazide 12.5 mg; losartan potassium 50 mg - losartan and diuretics - losartan and diuretics - for the treatment of hypertension, for patients in whom combination therapy is appropriate. to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.

ליפנור Իսրայել - եբրայերեն - Ministry of Health

ליפנור

cts chemical industries ltd, israel - ciprofibrate - קפסולות - ciprofibrate 100 mg - ciprofibrate - ciprofibrate - for the treatment of primary hyperlipidaemia resistant to appropriate dietary management, including hypercholesterolaemia, hypertriglyceridaemia and combined hyperlipidaemia.

רט-אויט ג'ל % 0.05 Իսրայել - եբրայերեն - Ministry of Health

רט-אויט ג'ל % 0.05

cts chemical industries ltd, israel - tretinoin - ג'ל - tretinoin 0.05 %w/w - tretinoin - tretinoin - treatment acne vulgaris.

רט-אויט קרם % 0.05 Իսրայել - եբրայերեն - Ministry of Health

רט-אויט קרם % 0.05

cts chemical industries ltd, israel - tretinoin - קרם - tretinoin 0.05 %w/w - tretinoin - tretinoin - acne vulgaris.

רט-א ויט קרם % 0.025 Իսրայել - եբրայերեն - Ministry of Health

רט-א ויט קרם % 0.025

cts chemical industries ltd, israel - tretinoin - קרם - tretinoin 0.025 %w/w - tretinoin - tretinoin - treatment of acne vulgaris.

רט-אויט ג'ל % 0.025 Իսրայել - եբրայերեն - Ministry of Health

רט-אויט ג'ל % 0.025

cts chemical industries ltd, israel - tretinoin - ג'ל - tretinoin 0.025 %w/w - tretinoin - tretinoin - treatment of acne vulgaris.

נוביטרופן 5 מג טבליות Իսրայել - եբրայերեն - Ministry of Health

נוביטרופן 5 מג טבליות

cts chemical industries ltd, israel - oxybutynin hydrochloride - טבליה - oxybutynin hydrochloride 5 mg - oxybutynin - oxybutynin - relief of symptoms associated with voiding in patients with uninhibited neurogenic and reflux neurogenic bladder.

אציקלו-וי 200 Իսրայել - եբրայերեն - Ministry of Health

אציקלו-וי 200

cts chemical industries ltd, israel - aciclovir - טבליה - aciclovir 200 mg - aciclovir - aciclovir - treatment of herpes simplex, infections of skin and mucous membranes including initial and recurrent genital herpes. suppression of recurrent herpes simplex infections. prophylaxis of herpes simplex infections in immune compromised patients. treatment of herpes zoster infections. for the treatment of chickenpox in certain groups at increased risk of severe varicella or its complications. these groups are as follows: patients over 13 years of age who are otherwise healthy. children over 12 months of age with chronic cutaneous or pulmonary condition, or receiving long term salicylate therapy. children receiving short or intermittent courses of aerosolized corticosteroids. the drug should not be taken if more than 24 hours passed from the onset of a typical chickenpox rash.